Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 24, 2023

Impact of Plasma ESR1 Mutations on Outcomes of First-Line Paclitaxel and Bevacizumab in Patients With Advanced ER+/HER2− Breast Cancer

Breast Cancer Research and Treatment


Additional Info

Breast Cancer Research and Treatment
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
Breast Cancer Res Treat 2023 Jul 01;200(2)271-279, MK Bos, SW Lam, G Motta, JCA Helmijr, CM Beaufort, E de Jonge, JWM Martens, E Boven, MPHM Jansen, A Jager, S Sleijfer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading